Hyaluronidase in Dermatology: Uses Beyond Hyaluronic Acid Fillers

Searle, Tamara; Ali, Faisal; Al‐Niaimi, Firas

doi:10.36849/jdd.2020.5416

Cited by 8 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In aesthetic plastic surgery, hyaluronidase is commonly used for over-correction and asymmetry, in which the dose of hyaluronidase is rather diverse and heterogeneous [147]. It is reported that the distribution, amounts, molecular weights and characteristics of HyA in scar tissue are different from those of normal tissue [21,148]. Low-molecular-weight fragments of HyA produced by hyaluronidase are known to stimulate angiogenesis and activate mesenchymal stem cells [144].…”

Section: Hyaluronidasementioning

confidence: 99%

Pharmacotherapy for Keloids and Hypertrophic Scars

Murakami,

Shigeki

2024

IJMS

View full text Add to dashboard Cite

Keloids (KD) and hypertrophic scars (HTS), which are quite raised and pigmented and have increased vascularization and cellularity, are formed due to the impaired healing process of cutaneous injuries in some individuals having family history and genetic factors. These scars decrease the quality of life (QOL) of patients greatly, due to the pain, itching, contracture, cosmetic problems, and so on, depending on the location of the scars. Treatment/prevention that will satisfy patients’ QOL is still under development. In this article, we review pharmacotherapy for treating KD and HTS, including the prevention of postsurgical recurrence (especially KD). Pharmacotherapy involves monotherapy using a single drug and combination pharmacotherapy using multiple drugs, where drugs are administered orally, topically and/or through intralesional injection. In addition, pharmacotherapy for KD/HTS is sometimes combined with surgical excision and/or with physical therapy such as cryotherapy, laser therapy, radiotherapy including brachytherapy, and silicone gel/sheeting. The results regarding the clinical effectiveness of each mono-pharmacotherapy for KD/HTS are not always consistent but rather scattered among researchers. Multimodal combination pharmacotherapy that targets multiple sites simultaneously is more effective than mono-pharmacotherapy. The literature was searched using PubMed, Google Scholar, and Online search engines.

show abstract

Section: Hyaluronidasementioning

confidence: 99%

Pharmacotherapy for Keloids and Hypertrophic Scars

Murakami,

Shigeki

2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Nowadays, commercial formulations of exogenous hyaluronidases include purified forms from bovine (BTH) and ovine testicles (OTH) and recombinant human hyaluronidase (rHuPH20) (Searle et al, 2020). Animal derived hyaluronidases are extracted from testis tissue, and are generally purified by series of multiple precipitation, fractionation and filtration steps (Farooqui and Srivastava, 1979;Lyon and Phelps, 1981;Kaya et al, 2015).…”

Section: Hyaluronidases: Adjuvants To Enhance the Diffusion Of Other Drugs And Agents To Correct Esthetic Filling Proceduresmentioning

confidence: 99%

Prospective Use of Brown Spider Venom Toxins as Therapeutic and Biotechnological Inputs

Gremski

Matsubara

Polli

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Brown spider (genus Loxosceles) venoms are mainly composed of protein toxins used for predation and defense. Bites of these spiders most commonly produce a local dermonecrotic lesion with gravitational spread, edema and hemorrhage, which together are defined as cutaneous loxoscelism. Systemic loxoscelism, such as hematological abnormalities and renal injury, are less frequent but more lethal. Some Loxosceles venom toxins have already been isolated and extensively studied, such as phospholipases D (PLDs), which have been recombinantly expressed and were proven to reproduce toxic activities associated to the whole venom. PLDs have a notable potential to be engineered and converted in non-toxic antigens to produce a new generation of antivenoms or vaccines. PLDs also can serve as tools to discover inhibitors to be used as therapeutic agents. Other Loxosceles toxins have been identified and functionally characterized, such as hyaluronidases, allergen factor, serpin, TCTP and knottins (ICK peptides). All these toxins were produced as recombinant molecules and are biologically active molecules that can be used as tools for the potential development of chemical candidates to tackle many medical and biological threats, acting, for instance, as antitumoral, insecticides, analgesic, antigens for allergy tests and biochemical reagents for cell studies. In addition, these recombinant toxins may be useful to develop a rational therapy for loxoscelism. This review summarizes the main candidates for the development of drugs and biotechnological inputs that have been described in Brown spider venoms.

show abstract

“…Hyaluronidase has been used for retrobulbar, peribulbar, and sub-Tenon's anaesthesia in eye surgery, as a ‘spreading agent’. It reduces tissue oedema, periorbital oedema, and helps re-absorption of subcutaneous hematomas [ 2 , 27 , 28 ]. It assists vitrectomy, that is the surgery of the retina, where vitreous requires removing (the gel-like substance that fills the middle portion of the eye) and replacing it with another solution [ 2 ] by degrading hyaluronic acid into disaccharide compounds and dissociating intercellular substance barrier to liquefy the vitreous [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

“…Hyaluronidase has been used to increase the duration and efficacy of anaesthesia; it hydrolysis the HA, increasing connective tissue permeability and collectively leading to a faster anaesthetic effect and a greater anaesthetized surface [ 28 ]. It has been used as an adjunct for inferior alveolar nerve blocks [ 29 ], intra-pulpal anaesthesia [ 30 ], or for craniectomy [ 31 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Scoping Review of Hyaluronidase Use in Managing the Complications of Aesthetic Interventions

2022

View full text Add to dashboard Cite

Background Hyaluronidase is used as an adjunct or main treatment to manage complications associated with cosmetic hyaluronic acid (HA) filler injections such as necrosis, blindness, hypersensitivity, delayed nodules, and poor aesthetic outcomes. Objective To systematically map the available evidence and identify the gaps in knowledge on the effectiveness of hyaluronidase use in managing the aesthetic complications associated with HA injections (vascular occlusion, blindness, nodules, delayed hypersensivity, granuloma, poor aesthetic outcome). Methods PubMed, Medline, Embase and Cochrane databases were used up to May 2022, to look for randomized clinical trials (RCTs), clinical trials, and retrospective case-control studies reporting on the use of hyaluronidase for managing the HA filler injection complications. Results The database search yielded 395 studies; of those 5 RCTs (all carried out in the USA) were selected (53 subjects), indicating the effectiveness of hyaluronidase for removal of un-complicated injected HA nodules (forearm, upper arm, or back skin). The follow-ups ranged from 14 days to 4 years. The amount of HA filler injected into each site varied from 0.2 to 0.4 mL. A dose dependent response was observed for most HA fillers. No major adverse reactions were reported. Overall, for removal of every 0.1 mL of HA filler they injected 1.25–37.5 units of hyaluronidase (single injections). When 3 consecutive weekly hyaluronidase injection was used much lower doses of 0.375–2.25 unit was utilised. There was no evidence in a form of RCTs, clinical trials, and retrospective case-control studies on the removal/reversal of HA injections in the facial skin, or management of over-corrections, inflammatory nodules, or tissue ischemia/necrosis associated with HA filler injection. Conclusion Based on studies on the forearm, upper arm and back skin, hyaluronidase can be used for the reversal of uncomplicated HA filler injection nodule. However, further adequately powered studies are warranted to establish the ideal treatment protocol/dose of hyaluronidase for reversal of HA filler injections in the facial region or management of complications associated with aesthetic HA injection. Level of Evidence III This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.

show abstract

Hyaluronidase in Dermatology: Uses Beyond Hyaluronic Acid Fillers

Cited by 8 publications

References 39 publications

Pharmacotherapy for Keloids and Hypertrophic Scars

Pharmacotherapy for Keloids and Hypertrophic Scars

Prospective Use of Brown Spider Venom Toxins as Therapeutic and Biotechnological Inputs

A Scoping Review of Hyaluronidase Use in Managing the Complications of Aesthetic Interventions

Contact Info

Product

Resources

About